Artificial Pancreas Development for Use in Emergency and Disaster Settings

Introduction: The Next Frontier in Diabetes Technology for Crisis Situations

The artificial pancreas represents one of the most significant breakthroughs in diabetes care, moving from experimental concepts to clinically validated systems that automate insulin delivery. Traditional artificial pancreas systems, however, are designed for stable home environments with reliable power, consistent supplies, and access to healthcare support. The challenge now is to adapt these systems for emergency and disaster settings—where every minute counts, infrastructure is compromised, and medical resources are scarce. Developing a resilient, portable, and user-friendly artificial pancreas for disaster response could dramatically reduce morbidity and mortality among individuals with type 1 diabetes (T1D) and insulin-dependent type 2 diabetes (T2D) during natural disasters, conflict zones, pandemics, or other mass-casualty events.

This article explores the state of the art in artificial pancreas technology, the unique constraints of emergency environments, design innovations currently in development, and the collaborative efforts required to bring these life-saving devices to the field. By expanding beyond the original scope, we examine clinical evidence, regulatory pathways, supply chain resilience, and the integration of artificial intelligence to make autonomous diabetes management a reality in the most challenging conditions.

Understanding the Artificial Pancreas: Components and Function

An artificial pancreas, also known as a closed-loop insulin delivery system, is a medical device that continuously monitors blood glucose levels and automatically delivers appropriate doses of insulin. The core components have evolved over decades, but the modern system typically includes three integrated parts:

Continuous Glucose Monitor (CGM): A small sensor inserted under the skin that measures interstitial glucose levels every few minutes, sending data to a controller via wireless transmission.
Insulin Pump: A wearable device that delivers rapid-acting insulin subcutaneously through a cannula. The pump can adjust basal rates and administer boluses based on CGM readings.
Control Algorithm: The "brain" of the system—a mathematical model implemented in software that interprets glucose data and commands the pump. Modern algorithms use predictive models, proportional-integral-derivative (PID) control, or model predictive control (MPC) to maintain glucose within a target range.

The first approved hybrid closed-loop systems (e.g., Medtronic MiniMed 670G/780G) still require user input for meals and exercise. Fully automated systems are in clinical trials, but none are yet ruggedized for emergencies. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has funded extensive research into closed-loop technology, laying the groundwork for disaster-adapted versions.

How Current Systems Fall Short in Disasters

Commercial artificial pancreas systems are designed for everyday use in controlled settings. They rely on cloud-based data sharing, smartphone apps, and frequent consumable replacements (sensors last 7–14 days, pump reservoirs 2–3 days). In a disaster, these assumptions break down. Power outages prevent charging; supply chains rupture; and internet connectivity vanishes. Furthermore, patients may be displaced, injured, or separated from caregivers. The need for a simplified, robust system that can operate independently of external infrastructure is urgent.

Challenges in Emergency and Disaster Settings: A Detailed Analysis

Disasters—whether natural (earthquakes, hurricanes, floods), man-made (conflict, industrial accidents), or biological (pandemics)—impose unique stressors on diabetes management. The World Health Organization (WHO) emphasizes that people with chronic conditions are disproportionately affected during emergencies. For insulin-dependent patients, the risks are acute: hyperglycemic hyperosmolar state (HHS), diabetic ketoacidosis (DKA), and severe hypoglycemia can become life-threatening within hours without proper management.

The challenges can be categorized into patient-level, device-level, and system-level factors.

Patient-Level Challenges

Displacement and stress: Evacuation disrupts routine monitoring and insulin storage. Stress hormones raise blood glucose, requiring more frequent adjustments.
Inability to self-manage: Injuries, cognitive load, or lack of training may prevent patients from operating complex devices. A disaster-adapted artificial pancreas must require minimal user intervention.
Loss of supplies: CGMs, infusion sets, insulin vials, and batteries are often lost or destroyed. The system must accept alternative supplies or operate with low-frequency consumable changes.

Device-Level Challenges

Power and connectivity: Devices must function without grid power, cellular networks, or Wi-Fi. Solar charging, hand-cranking, or long-life batteries (e.g., lithium polymer cells lasting weeks) are essential. Bluetooth Low Energy (BLE) can operate peer-to-peer without infrastructure, but algorithms must store data locally.
Environmental toughness: Temperature extremes (heat, cold), humidity, water immersion, dust, and shock are common. Military-grade ingress protection (IP68) and rugged enclosures are needed. Sensors must maintain accuracy despite barometric pressure changes or altitude.
Interference and reliability: Electromagnetic interference from communication equipment or metal debris can disrupt wireless signals. Fail-safe modes (e.g., manual insulin delivery via a backup button) are mandatory.

System-Level Challenges

Scalability and deployment speed: A disaster may affect thousands of diabetes patients. Devices must be pre-positioned in stockpiles and quickly distributed. Training non-medical personnel (first responders, volunteers) to assist with setup is critical.
Regulatory and liability issues: Emergency use authorizations (EUAs) from agencies like the FDA can accelerate approval, but device performance standards must still be met. The FDA’s Emergency Use Authorization pathway provides a framework for COVID-19-related devices and could be adapted for diabetes technology.
Supply chain resilience: Manufacturing must be geographically distributed to avoid single-point failures. Raw materials (sensors, polymers, insulin) should be sourced from multiple vendors. Military and humanitarian logistics networks (e.g., UNICEF, Médecins Sans Frontières) could integrate these devices into their medical kits.

Design Considerations for a Disaster-Ready Artificial Pancreas

Based on the above challenges, engineers and clinicians have proposed a set of design requirements that go far beyond commercial specifications. The following table summarizes key features:

Requirement	Specification	Rationale
Portability	Weight under 200g, fits in a pocket or on a belt	Easy to carry during evacuation; no need for backpacks
Durability	IP68, drop-tested to 2 meters, temperature range -10°C to 50°C	Withstands extreme weather, rough handling, and immersion
Power efficiency	Battery life ≥30 days on a single charge; solar or kinetic charging option	No grid access; reduces need for battery swaps in the field
Consumable longevity	Sensor life ≥30 days, insulin reservoir ≥7 days	Minimizes resupply frequency; reduces waste
Simplicity of operation	Single-button start, voice-guided setup, color-coded status	Usable by patients with limited health literacy or injury
Manual override	Physical button to deliver a fixed insulin bolus or suspend delivery	Critical if algorithm fails or CGM malfunctions
Offline operation	Full functionality without internet; local storage of data for later download	No reliance on cloud or cellular networks
Interoperability	Standardized connectors, compatible with generic insulin vials and infusion sets	Reduces dependency on proprietary consumables

Human Factors and Training

Even the most robust device fails if users cannot operate it under duress. Human-factors engineering must prioritize intuitive interfaces: visual icons, haptic feedback, and auditory alarms that can be understood across languages. Training modules should be delivered via simple printed cards or downloadable offline content. In a disaster, peer-to-peer training by other diabetes patients may be the most effective model. The design should also accommodate caregivers with no prior diabetes experience—perhaps a "first responder mode" that automatically transitions to a safe basal rate upon activation.

Recent Innovations and Prototypes

Several research groups and nonprofit organizations are actively developing artificial pancreas systems tailored for emergency use. While none are yet commercially available, prototypes have shown promise in laboratory simulations and field exercises.

Solar-Powered Closed-Loop Systems

Researchers at the University of Cambridge and the University of Virginia have collaborated on a solar-rechargeable artificial pancreas that uses low-power electronics and a high-efficiency photovoltaic panel on the pump housing. Early tests demonstrated continuous operation for 28 days without battery replacement, even in simulated cloudy conditions. The algorithm runs on a microcontroller consuming only 10 mW, allowing the device to be powered by a small solar cell similar to those used in calculators. This approach eliminates the need for disposable batteries, a major advantage in remote areas.

Ruggedized CGM with Extended Wear

Companies like Dexcom and Abbott have developed extended-wear CGM sensors (e.g., Dexcom G7's 10-day wear, Abbott Freestyle Libre 3's 14-day). For emergency settings, researchers are exploring sensors that last 30–60 days using advanced enzyme coatings and biocompatible membranes that resist biofouling. A 2021 study in Diabetes Technology & Therapeutics reported a prototype sensor that maintained accuracy within 15% of reference blood glucose for 45 days in animal models. Further work is needed to miniaturize and stabilize the electronics.

Manual Override and "Tactical" Modes

Some designs incorporate a physical "disaster mode" switch that locks the algorithm to a conservative basal rate (e.g., 50% of typical basal) while disabling automatic boluses. This prevents dangerous corrections when CGM readings may be unreliable due to sensor lag or interference. A manual bolus button can deliver a fixed amount (e.g., 0.5U increments) with a safety lock to prevent stacking. Such features parallel "tactical" medical devices used by military medics, emphasizing simplicity and fail-safe operation.

Integration with Emergency Communication Systems

Even without internet, devices can communicate via mesh networks (e.g., LoRa, Zigbee) to relay patient status to a central triage point. A prototype developed by a DARPA-funded team uses a long-range radio to broadcast glucose trends and device battery levels to a handheld receiver carried by medics. This enables remote monitoring of multiple patients in a field hospital without tying up staff. The system also logs data for later review to optimize care protocols.

Clinical Validation and Regulatory Pathways

Before any disaster-adapted artificial pancreas can be deployed, it must undergo rigorous clinical testing to ensure safety and efficacy under realistic conditions. Traditional clinical trials are expensive and slow. For emergency devices, regulators may accept alternative evidence, such as:

In silico simulations using validated metabolic models (e.g., the UVA/Padova FDA-accepted simulator)
Controlled human trials in simulated disaster environments (e.g., camping in extreme weather with limited food and water)
Use of "emergency use" exemptions for small-scale deployment during actual disasters with informed consent

The FDA and European Medicines Agency (EMA) have established frameworks for digital health devices that include adaptive algorithms. A 2022 FDA guidance on artificial pancreas systems encourages modular designs that can be updated remotely—a feature useful for pushing new algorithms to field devices. However, cybersecurity and algorithm transparency remain concerns, especially in conflict zones where devices might be tampered with.

Ethical Considerations

Deploying experimental devices in emergencies raises ethical issues around informed consent, equity of access, and liability. Patients may feel compelled to accept a device due to lack of alternatives. Manufacturers must provide clear warnings and ensure that use is voluntary. International bodies like the WHO's Ethics and Governance of AI in Health Emergencies offer guidelines for responsible innovation.

Future Outlook: Toward Full Autonomy and Global Resilience

The vision for the next generation of artificial pancreas systems is a device that can be left on a shelf for months, then activated in minutes by a non-specialist, and function autonomously for weeks without resupply. Achieving this requires convergence of several technologies:

Ultra-low-power electronics: Advances in microprocessors (e.g., ARM Cortex-M0+ with energy harvesting) enable continuous glucose sensing and algorithm execution on sub-milliwatt power.
Smart materials: Self-healing hydrogels for sensor sites can extend wear time and reduce inflammation. Insulin depots using glucose-responsive polymers could release insulin in response to glucose concentration, acting as a chemical failsafe.
Machine learning for fault detection: Algorithms can learn to detect sensor drift, pump occlusion, or insulin degradation and alert the user or automatically switch to a backup mode.
Global stockpile management: Humanitarian organizations could pre-position devices in disaster-prone regions, with a shelf life of 5+ years. Devices should use standardized insulin cartridges that also fit conventional pumps to ensure supply flexibility.

Collaboration between diabetes technology companies, military research labs, humanitarian agencies, and academic institutions is accelerating progress. The JDRF (Juvenile Diabetes Research Foundation) has funded several projects focused on emergency applications, recognizing that disaster preparedness is a key pillar of diabetes advocacy. In parallel, open-source artificial pancreas projects (e.g., OpenAPS, Loop) have demonstrated that community-driven development can produce low-cost, adaptable systems—an approach that could be leveraged for low-resource settings.

Conclusion: A Call to Action

The artificial pancreas has already transformed millions of lives. Extending this technology to emergency and disaster settings is not merely a technical challenge—it is a moral imperative. Climate change is increasing the frequency and severity of natural disasters; geopolitical instability creates prolonged humanitarian crises; and pandemics strain healthcare systems worldwide. Patients with diabetes should not have to choose between safety at home and survival during emergencies. By investing in ruggedized, autonomous, and accessible artificial pancreas systems, we can ensure that the most vulnerable are protected when they need it most. Researchers, regulators, manufacturers, and emergency planners must work together to move these innovations from prototype to practice—because in a disaster, every hour of effective blood glucose control can be the difference between life and death.

For further reading, consult the Diabetes UK emergency guidance and the 2018 review on diabetes technology in humanitarian settings by Khavandi et al.